linjc16/ctgov huggingface dataset:
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR

Study Overview
=================
Brief Summary
-----------------
It is generally assumed that renal blood flow is symmetric in the absence of renal artery stenosis. The importance of studying the function of both kidneys separately is because it cannot be assumed that they are functionally equal.The aim of the present study is to evaluate whether this is really in patients with essential hypertension and/or moderate kidneys loss.

Detailed Description
-----------------
To validate color Doppler ultrasonography of renal arteries for the assessment of renal blood flow (RBF), we comparing left and right RBF estimates and their sum (total RBF) by echo-Doppler with data obtained by 99mTc-DTPA scintigraphy in 50 patients with hypertension and/or moderate renal failure, compared with 30 normal control subjects.

Official Title
-----------------
Color-Doppler Ultrasonography vs 99mTc-DTPA Scintigraphy to Assess the Renal Blood Flow

Conditions
-----------------
Hypertension, Renal Failure

Intervention / Treatment
-----------------
* Procedure: Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hypertension Patients with moderate renal insufficiency Normal subjects Exclusion Criteria: Patients with solitary kidney function Patients with renal artery stenosis Patients underwent renal angioplasty and stenting

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Color-Doppler Ultrasonography, Renal scintigraphy, Kidney failure, GFR
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).

Study Overview
=================
Brief Summary
-----------------
Patients with aggressive Non-Hodgkin-lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates. However, patients with relapsed lymphoma still have a poor prognosis. High dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the treatment of choice for these patients. An ASCT allows patients to receive much higher doses of chemotherapy than usual, to improve the chances of curing the disease. The high-dose of chemotherapy destroys the cells in the patients bone marrow and then the patients own cells from either the bone marrow or peripheral blood are used to rescue the patient from intensive treatment. High-dose chemotherapy with autologous stem cell (either bone marrow or peripheral blood) transplantation is used in the treatment of Intermediate/High grade NHL with poor risk disease and in second remission at the Royal Marsden Hospital. The purpose of the present analysis is to determine independent prognostic factors correlated with the long-term outcome of patients with NHL who received an ASCT between January 1991 and June 2005. Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment. All patients accrued will give informed consent to participate in the study for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. The results of the analysis will be published in a peer-reviewed medical journal. This will include patients treated at the royal Marsden Hospital only.

Conditions
-----------------
Non-Hodgkins Lymphoma

Intervention / Treatment
-----------------
* Procedure: Autologous stem cell transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - a) Age over 18 b) Patients with Non-Hodgkin's Lymphoma who have received an autologous stem cell transplant in the past. c) Informed written consent Exclusion Criteria: a) Medical or psychiatric conditions that compromise the patient's ability to give informed consent b) HIV positive or AIDS related lymphoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Autologous stem cell transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.

Official Title
-----------------
A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Biological: CV787 (CG7870)


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: CV787 (CG7870)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the safety, tolerability, and the maximum tolerated dose of CG7870 when administered intravenously to patients with progressive metastatic hormone refractory prostate cancer |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate prostate-specific antigen (PSA) response rates, duration of response, and time to disease progression |  |  | 
| To evaluate other clinical efficacy responses observed |  |  | 
| To evaluate the systemic pharmacokinetics of CG7870 after intravenous administration |  |  | 
| To monitor the immune response to CG7870 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hormone Refractory Metastatic Prostate Cancer
Study of Body Composition Methodology in Young Children (InfantPod)

Study Overview
=================
Brief Summary
-----------------
The InfantPod study is a cross-sectional study designed to determine how practical and precise a body composition method is for measuring body fat and lean tissue in infants and children ages 5 months to 3 years.

Official Title
-----------------
Development of a Body Composition Method for Infants and Children

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children between ages of 5 months and 3 years Exclusion Criteria: Child that has any condition that may affect growth Child that has any chronic disease Child that has any carbohydrate metabolism disorder Child that takes any medications that may interfere with study parameters as determined by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 5 Months
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Full-term healthy infants ages 5 months to 3 years. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutrition, Body Fat, Infant, Healthy Babies
Study of Nesvacumab (REGN910/ SAR307746)

Study Overview
=================
Brief Summary
-----------------
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) administered IV every 2 weeks.

Official Title
-----------------
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Drug: nesvacumab (REGN910/ SAR307746)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of advanced solid malignancy. ECOG performance status 0 - 1 Adequate hepatic, renal and bone marrow function At least 3 weeks since last dose of chemotherapy, hormonal therapy or radiotherapy At least 6 weeks since last dose of bevacizumab At least 4 weeks since last surgery At least 4 weeks since last dose of investigational treatment Exclusion Criteria: Patients with brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence of central nervous system involvement Patients with serious non healing wound or acute ulcer Either systolic blood pressure >150 mm Hg or diastolic blood pressure >95 mm Hg Patients with medical history of myocardial infarction, unstable angina pectoris, coronary/ peripheral artery bypass graft, congestive heart failure or ventricular arrhythmia Patients with deep vein thrombosis or pulmonary embolism within last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br>Dose 1 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Cohort 2<br>Dose 2 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Cohort 3<br>Dose 3 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Cohort 4<br>Dose 4 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Cohort 5<br>Dose 5 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Expansion Cohort 1<br>Dose 4 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |
| Experimental: Expansion Cohort 2<br>Dose 5 | Drug: nesvacumab (REGN910/ SAR307746)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) in patients with advanced solid malignancies |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK/PD profile |  | 28 days | 
| Immunogenicity |  | 28 days | 
| Anti-tumor activity |  | 28 days | 
| Correlative biomarkers |  | 28 days |
The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate whether it is possible to predict the success of trabeculectomy in patients with glaucoma through the examination of mediators of wound healing in anterior chamber fluid. The success rate of trabeculectomy with mitomycin C in the literature is about 75%. This leads on the question why 25% of the patients received trabeculectomy are not sufficient treated and have not a long-term IOP reduction. Precisely this question is to be examined by the study.

Official Title
-----------------
The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy

Conditions
-----------------
Glaucoma, Trabeculectomy, Wound Healing

Intervention / Treatment
-----------------
* Procedure: Trabeculectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with glaucoma with a trabeculectomy required 60 eyes of 60 patients, The ratio of female / male is not involved. Eye pressure under local therapy: 20mmHg and above (corrected with pachymetry table). age of at least 18 years Exclusion Criteria: all patients not included in the group of inclusion criteria. less than 50yl anterior chamber fluid could be collected during the operation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glaucoma patients<br> | Procedure: Trabeculectomy<br>* Trabeculectomy with mitomycin C<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Official Title
-----------------
A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.

Conditions
-----------------
Choroidal Neovascularization

Intervention / Treatment
-----------------
* Drug: ranibizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: active choroidal neovascularization Exclusion Criteria: pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ranibizumab<br>ranibizumab 0.5mg intravitreal injection | Drug: ranibizumab<br>* 0.5mg intravitreal injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measures for safety and tolerability |  | Mean change in visual acuity from baseline to 6 months & 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary outcome measures for efficacy |  | Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
choroidal neovascularization, Choroidal Neovascularization Not related to Age-Related Macular Degeneration
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Study Overview
=================
Brief Summary
-----------------
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

Detailed Description
-----------------
Registry study to examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

Official Title
-----------------
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Pimecrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males and females greater than or equal to 2 years and less than or equal to 17 years at enrollment diagnosis of atopic dermatitis (confirmed by treating physician) applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks Exclusion Criteria: past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease past or present use of oral immunosuppressive therapy

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus | Drug: Pimecrolimus<br>* Pimecrolimus 1% cream<br>* Other names: Elidel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence rate of systemic malignancies in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream |  | 10 years of observation with 6-month reporting intervals | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence rate of lymphoma in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream |  | 10 years of observation with 6-month reporting intervals | 
| The incidence rate of thyroid cancer in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream |  | 10 years of observation with 6-month reporting intervals | 
| The incidence rate of cutaneous malignancy in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream |  | 10 years of observation with 6-month reporting intervals | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atopic dermatitis eczema pediatric pimecrolimus malignancy
Pyrosequencing of the BRAFV600E Mutation

Study Overview
=================
Brief Summary
-----------------
To investigate the diagnostic efficiency of pyrosequencing for the mutant BRAF allele in ultrasound (US)-guided fine needle aspiration biopsies (FNAB) of thyroid incidentalomas.

Official Title
-----------------
Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas

Conditions
-----------------
Thyroid Neoplasms

Intervention / Treatment
-----------------
* Procedure: ultrasound-guided fine needle aspiration biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with thyroid nodule larger than 1 cm, or nodule smaller than 1 cm that required further evaluation because of suspicious ultrasound findings Exclusion Criteria: Patients who refuse participation.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy | Procedure: ultrasound-guided fine needle aspiration biopsy<br>* Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pyrosequencing, BRAFV600E mutation, Thyroid incidentaloma, Ultrasound-guided fine-needle aspiration biopsy
An Innovative Approach to Automated Carbon Dioxide Angiography During Endovascular Abdominal Aortic Aneurysm Repair

Study Overview
=================
Brief Summary
-----------------
The study aims to perform Endovascular Aortic Repair procedures with CO2-Angiography using a standardized an operative Protocol

Official Title
-----------------
CO2-EVAR - An Innovative Approach to Automated Carbon Dioxide Angiography During Endovascular Abdominal Aortic Aneurysm Repair - (Proof of Concept Study)

Conditions
-----------------
Abdominal Aortic Aneurysm

Intervention / Treatment
-----------------
* Procedure: Endovascular Aortic Repair using Carbon Dioxide Angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Male, female Patients with indication for AAA Informed consent achievement Exclusion Criteria: Severe COPD (Chronic Obstructive Pulmonary Disease) Known atrium- or ventricular septal defect with right-left-shunt Severe renal arteries atherosclerosis Ruptured AAA Current partecipation in other interventional studies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical Success | Technical success to assess the renal ostia and the hypogastric arteries (defined as 100% accuracy correlated to the iodinated contrast agent angiography or IVUS/FUSION techniques) | 30 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image Quality | Image quality for guiding the procedure defined as good for stent-graft implantation or low not allowing stent-graft implantation | 30 Days | 
| Endoleak Detection | Type I-IV endoleak detection | 30 Days | 
| CO2 Quantity | Amount of CO2 at each deployment step (renal arteries, right/left hypogastric artery, final angiography) | 30 Days | 
| Aneurysm Exclusion | Aneurysm exclusion without type I or III endoleaks at the CT scan at discharge | 30 Days | 
| Adverse Events | Any adverse event within 24 hours | 30 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endovascular Aortic Repair